Satavaptan

Drug Profile

Satavaptan

Alternative Names: Aquilda; SR 121463B; SR-121463

Latest Information Update: 02 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class Antihypertensives; Heart failure therapies; Morpholines; Small molecules; Spiro compounds
  • Mechanism of Action Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Glaucoma; Heart failure; Hypertension; Hyponatraemia; Liver cirrhosis; Nephrotic syndrome

Most Recent Events

  • 26 Apr 2009 Adverse events data from a trial in liver cirrhosis presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
  • 31 Dec 2008 Discontinued - Phase-III for Cirrhosis in Argentina (PO)
  • 31 Dec 2008 Discontinued - Phase-III for Cirrhosis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top